# Nanjing Leads Biolabs

Source: https://onco.cc/companies/nanjing-leads-biolabs/  
OnCo record `nanjing-leads-biolabs` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nanjing Leads Biolabs is a Hong Kong-listed Chinese biotechnology company running 8 late-stage cancer trials of LBL-024 and LBL-034 in triple-negative breast cancer, non-small-cell lung cancer and hepatocellular carcinoma.

## Summary

Nanjing Leads Biolabs, based in Nanjing, China, is a biotechnology company founded in 2012 that listed on the Hong Kong Stock Exchange on 25 July 2025. In August 2026 China's drug regulator accepted, with priority review, its application to market LBL-024 (opamtistomig), a bispecific antibody against PD-L1 and 4-1BB, for previously treated advanced extrapulmonary neuroendocrine carcinoma. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials, testing LBL-024 and LBL-034 in triple-negative breast cancer, non-small-cell lung cancer, hepatocellular carcinoma, oesophageal cancer and multiple myeloma. The largest, NCT05170958 (A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumours), plans to enrol 396 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Nanjing Leads Biolabs Co.,Ltd
- Tags: ctgov-sponsor
- HQ: Nanjing
- Type: biotech
- Website: https://www.leadsbiolabs.com
- Ticker: 9887.HK

## Notes

- Freshened 29 October 2026 from the company's 2025 annual report (listing date, founding year, IPO proceeds) and its HKEX announcements. Its 2025 licence of LBL-047 to Dianthus Therapeutics is for autoimmune disease, not cancer, so it is not described here.

## Sources

- Official website: https://www.leadsbiolabs.com
- HKEX: 2025 annual report: https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042403304.pdf
- HKEX: LBL-024 marketing application accepted by NMPA (21 August 2026): https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082100348.pdf
- ClinicalTrials.gov: trials led by Nanjing Leads Biolabs: https://clinicaltrials.gov/search?lead=Nanjing%20Leads%20Biolabs%20Co.%2CLtd

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- trials: [A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]](https://onco.cc/trials/nct06783647/), [A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]](https://onco.cc/trials/nct07111546/), [A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma](https://onco.cc/trials/nct07791758/), [A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma](https://onco.cc/trials/nct06049290/), [A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors](https://onco.cc/trials/nct05170958/), [A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]](https://onco.cc/trials/nct07331155/), [A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]](https://onco.cc/trials/nct07390383/), [A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer](https://onco.cc/trials/nct07042802/), [A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer](https://onco.cc/trials/nct07281976/)

---
JSON: https://onco.cc/api/v1/entities/nanjing-leads-biolabs.json